Dexpropranolol
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Dexpropranolol
- DrugBank Accession Number
- DB03322
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 259.3434
Monoisotopic: 259.157228921 - Chemical Formula
- C16H21NO2
- Synonyms
- (+)-1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
- (+)-Propranolol
- (R)-(+)-propranolol
- 2R-Propranolol
- D-Propranolol
- Dexpropranolol
- R (+)-Propanolol
- R-(+)-Propranolol
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide Abaloparatide may increase the hypotensive activities of Dexpropranolol. Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Dexpropranolol. Acebutolol Acebutolol may increase the arrhythmogenic activities of Dexpropranolol. Aceclofenac Aceclofenac may decrease the antihypertensive activities of Dexpropranolol. Acemetacin Acemetacin may decrease the antihypertensive activities of Dexpropranolol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Naphthalenes
- Sub Class
- Not Available
- Direct Parent
- Naphthalenes
- Alternative Parents
- Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- 1,2-aminoalcohol / Alcohol / Alkyl aryl ether / Amine / Aromatic homopolycyclic compound / Ether / Hydrocarbon derivative / Naphthalene / Organic nitrogen compound / Organic oxygen compound
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- propranolol (CHEBI:8736)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- PG6KY07UD7
- CAS number
- 5051-22-9
- InChI Key
- AQHHHDLHHXJYJD-CQSZACIVSA-N
- InChI
- InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3/t14-/m1/s1
- IUPAC Name
- (2R)-1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
- SMILES
- CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
References
- General References
- Not Available
- External Links
- KEGG Compound
- C11193
- PubChem Compound
- 21138
- PubChem Substance
- 46504537
- ChemSpider
- 19877
- BindingDB
- 60973
- ChEBI
- 8736
- ChEMBL
- CHEMBL275742
- ZINC
- ZINC000000020240
- PDBe Ligand
- SNP
- Wikipedia
- Propranolol
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0794 mg/mL ALOGPS logP 3.03 ALOGPS logP 2.58 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 14.09 Chemaxon pKa (Strongest Basic) 9.67 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 41.49 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 76.83 m3·mol-1 Chemaxon Polarizability 30.05 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9944 Blood Brain Barrier - 0.9031 Caco-2 permeable + 0.6942 P-glycoprotein substrate Substrate 0.7079 P-glycoprotein inhibitor I Inhibitor 0.5588 P-glycoprotein inhibitor II Non-inhibitor 0.8383 Renal organic cation transporter Non-inhibitor 0.8177 CYP450 2C9 substrate Non-substrate 0.7898 CYP450 2D6 substrate Substrate 0.8918 CYP450 3A4 substrate Non-substrate 0.6463 CYP450 1A2 substrate Inhibitor 0.9106 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.924 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8487 Ames test Non AMES toxic 0.9392 Carcinogenicity Non-carcinogens 0.9097 Biodegradation Not ready biodegradable 0.9871 Rat acute toxicity 2.5625 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9185 hERG inhibition (predictor II) Inhibitor 0.7092
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-1090000000-5fdb7f81d44011a66b78 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-052g-5920000000-5195f33ce9888e355673 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-006t-9000000000-b17572eaeffb2faff211 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-3900000000-a33343f6f0a34f064538 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-05mo-9700000000-53721b0cc608f3eeebb4 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-1900000000-53ebb2ea9bdb7ef235ee Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 171.2734556 predictedDarkChem Lite v0.1.0 [M-H]- 160.42273 predictedDeepCCS 1.0 (2019) [M+H]+ 171.2165556 predictedDarkChem Lite v0.1.0 [M+H]+ 162.78072 predictedDeepCCS 1.0 (2019) [M+Na]+ 171.1968556 predictedDarkChem Lite v0.1.0 [M+Na]+ 168.87387 predictedDeepCCS 1.0 (2019)
Drug created at June 13, 2005 13:24 / Updated at February 21, 2021 18:51